phosphatidylcholine (18:0/18:2)

A phosphatidylcholine 36:2 in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C18:2 respectively.


A phosphatidylcholine 40:1 in which the acyl groups specified at positions 1 and 2 are (9Z)-octadecenoyl and docosanoyl respectively.


A phosphatidylcholine 34:1 in which the two acyl substituents at positions 1 and 2 are specified as oleoyl and palmitoyl respectively.


phosphatidylcholine 29:1

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 28 carbons in total with 1 double bond.


phosphatidylcholine (P-42:3)

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the unspecified alk-1-enyl and acyl groups at positions 1 and 2 contain 42 carbon atoms in total with 3 additional double bonds in the acyl moiety.


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as 5-oxovaleroyl.


A sphingomyelin in which the sphingoid component is specified as C17-sphinganine.


sphingomyelin 41:2

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 41 with 2 double bonds.


ammonium ion derivative

A derivative of ammonium, NH4(+), in which one (or more) of the hydrogens bonded to the nitrogen have been replaced with univalent organyl groups. The substituting carbon of the organyl group must not itself be directly attached to a heteroatom (thereby excluding protonated amides, hemiaminals, etc).


A phosphatidylcholine O-36:2 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and (11Z,14Z)-eicosadienoyl respectively.


A phosphatidylcholine 36:2 in which the acyl groups specified at positions 1 and 2 are (9Z,12Z)-octadecadienoyl and octadecanoyl respectively.


citicoline

A member of the class of  phosphocholines that is the chloine ester of CDP. It is an intermediate obtained in the biosynthetic pathway of structural phospholipids in cell membranes.


phosphatidylcholine 38:7

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 38 carbons in total with 7 double bonds.


phosphatidylcholine 31:1

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 31 carbons in total with 1 double bond.


ELAIDYLPHOSPHOCHOLINE

A phosphocholine that is the mono-1-elaidyl ester of phosphocholine


A phosphatidylcholine 42:4 in which the acyl groups specified at positions 1 and 2 are (6Z,9Z,12Z)-octadecatrienoyl and (15Z)-tetracosenoyl respectively.


phosphatidylcholine P-36:4

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups at positions 1 and 2 contain 36 carbon atoms in total with 4 additional double bonds.


A phosphatidylcholine 34:3 in which the acyl groups specified at positions 1 and 2 are palmitoyl and (9Z,12Z,15Z)-octadecatrienoyl (alpha-linolenoyl) respectively.


phosphatidylcholine (18:2/20:4)

A phosphatidylcholine 38:6 in which the fatty acyl groups at positions 1 and 2 are specified as C18:2 and C20:4 respectively.


phosphatidylcholine O-45:1

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 45 carbons and 1 double bond.


lysophosphatidylcholine 18:2

A lysophosphatidylcholine in which the acyl group (position not specified) contains 18 carbons and 2 double bonds.


A N-octadecenolsphingosine-1-phosphocholine in which the acyl group specified is 9Z-octadecenoyl.


A phosphatidylcholine O-36:3 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and (8Z,11Z,14Z)-eicosatrienoyl respectively.


phosphatidylcholine O-36:5

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 36 carbons and 5 double bonds.


phosphatidylcholine (P-40:3)

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the unspecified alk-1-enyl and acyl groups at positions 1 and 2 contain 40 carbon atoms in total with 3 additional double bonds in the acyl moiety.


A phosphatidylcholine 32:1 in which the acyl groups at C-1 and C-2 are tetradecanoyl and (9Z)-octadecenoyl respectively.


phosphatidylcholine 22:4

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 22 carbons in total with 4 double bonds.


phosphatidylcholine 40:2

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 40 carbons in total with 2 double bonds.


A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups are specified as (1Z)-hexadecenyl and tetradecanoyl respectively.


A 1-O-alkyl-2-O-arachidonoyl-sn-glycero-3-phosphocholine where the alkyl group is specified as hexadecyl.


phosphatidylcholine O-44:3

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 44 carbons and 3 double bonds.


phosphatidylcholine 30:1

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 30 carbons in total with 1 double bond.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl substituents at positions 1 and 2 are specified as palmitoyl and butanoyl respectively.


A phosphatidylcholine 40:7 in which the acyl groups at C-1 and C-2 are (11Z)-octadecenoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.


A phosphatidylcholine 40:2 in which the acyl group specified at positions 1 and 2 is (11Z)-eicosenoyl respectively.


A phosphatidylcholine 38:6 in which the acyl groups specified at positions 1 and 2 are (9Z)-octadecenoyl and (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl respectively.


A phosphatidylcholine 38:4 in which the acyl groups at positions 1 and 2 are specified as oleoyl and (8Z,11Z,14Z)-icosatrienoyl respectively.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 27 carbons and 0 double bonds.


A sphingomyelin in which the sphingoid component is specified as tetradecasphingosine.


sphingosylphosphorylcholine

A phosphosphingolipid consisting of sphingosine having a phosphocholine moiety attached to its primary hydroxyl group.


dihydrochanoclavine-I aldehyde(1+)

A cationic ergot alkaloid that is the conjugate acid of dihydrochanoclavine-I aldehyde, obtained by protonation of the secondary amino group; major species at pH 7.3.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 24 carbons and 0 double bonds and is 2-hydroxylated.


sphingomyelin 45:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 45 with 1 double bond.


A phosphatidylcholine 42:1 in which the acyl groups specified at positions 1 and 2 are docosanoyl and (11Z)-eicosenoyl respectively.


lysophosphatidylcholine 6:0

A lysophosphatidylcholine in which the remaining acyl group is specified as hexanoyl (caproyl). If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.


A lysophosphatidylcholine 16:0 in which the acyl group is specified as palmitoyl (hexadecanoyl) and is located at position 2.


A sphingomyelin d18:1 in which the N-acyl group is specified as (13Z)-docosenoyl.


A sphingomyelin in which the total number of carbons in the fatty acyl group is 26 with 1 double bond.


A phosphatidylcholine 38:6 in which the acyl groups at C-1 and C-2 are specified as palmitoyl and (4E,7E,10E,13E,16E,19E)-docosahexaenoyl respectively.


phosphatidylcholine O-40:1

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 1 double bond.


A phosphatidylcholine 36:3 in which the acyl group specified at positions 1 and 2 are hexadecanoyl and (8Z,11Z,14Z)-eicosatrienoyl respectively.


A sphingomyelin 33:1 obtained by formal condensation of the carboxy group of heptadecanoic acid with the amino group of hexadecasphingosine-1-phosphocholine.


phosphatidylcholine 36:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 36 carbons in total and 0 double bonds.


phosphatidylcholine (20:1/20:4)

A phosphatidylcholine 40:5 in which the fatty acyl groups at positions 1 and 2 are specified as C20:1 and C20:4 respectively.


An N-hexadecanoyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 16 carbons and 0 double bonds.


phosphatidylcholine 32:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 0 double bonds.


A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the acyl and alkyl groups are specified as hexadecanoyl (palmitoyl) and hexadecyl respectively.


phosphatidylcholine 25:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 25 carbons in total with no double bonds.


phosphatidylcholine 48:2

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 48 carbons in total with 2 double bonds.


A  phosphatidylcholine 38:1 in which the acyl groups specified at positions 1 and 2 are eicosanoyl and (11Z)-octadecenoyl respectively.


An N-acylhexadecasphingosine-1-phosphocholine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).


A phosphocholine carrying an O-(4-diazoniophenyl) substituent.


lysophosphatidylcholine 26:0

A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 26 carbons and 0 double bonds.


A sphingomyelin in which the sphingoid component is specified as icosaphytosphingosine.


phosphatidylcholine 35:3

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 35 carbons in total with 3 double bonds.


A phosphatidylcholine 38:1 in which the acyl groups at positions 1 and 2 are specified as (9Z)-octadecenoyl and eicosanoyl respectively.


A phosphatidylcholine 38:5 in which the acyl groups at positions 1 and 2 are hexadecanoyl and (4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl respectively.


A primary ammonium ion that is the conjugate acid of thiamine(1+) resulting from the protonation of the primary amino group.


A lysophosphatidylcholine 17:0 in which the acyl group at position 1 is 1-heptadecanoyl and the hydroxy group at position 2 is unsubstituted.


A phosphatidylcholine O-30:2 in which the alkyl and acyl group specified at positions 1 and 2 are (9Z)-hexadecenyl and (9Z)-tetradecenoyl respectively.


A phosphatidylcholine O-36:0 in which the alkyl and acyl groups specified at positions 1 and 2 are octadecyl and octadecanoyl respectively.


A N-hexadecenoylsphingosine-1-phosphocholine in which the amino group of sphingosine is in amide linkage with a 9Z-hexadecenoyl fatty acid.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the 1-acyl group is specified as palmitoyl.


Any lysoglycerophosphocholine having an oxidized fatty acyl chain at sn-2. Major species at pH 7.3.


A phosphatidylcholine 38:4 in which one acyl group has 16 carbons and is fully saturated while the other has 22 carbons and 4 double bonds (position not specified).


phosphatidylcholine 34:6

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 34 carbons in total with 6 double bonds.


A quaternary ammonium ion that is (S)-cis-N-methylcanadine in which the hydrogen at position 14 is substituted by a hydroxy group.


A phosphatidylcholine 38:6 in which the acyl groups specified at positions 1 and 2 are (9Z,12Z)-octadecadienoyl and (5Z,8Z,11Z,14Z)-icosatetraenoyl respectively.


A phosphatidylcholine 34:3 in which the acyl groups specified at positions 1 and 2 are palmitoyl and (6Z,9Z,12Z)-octadecatrienoyl (gamma-linolenoyl) respectively.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups specified at positions 1 and 2 are palmitoyl and (11Z)-eicosenoyl respectively.


phosphatidylcholine (16:0/18:1)

A phosphatidylcholine 34:1 in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C18:1 respectively.


phosphatidylcholine O-32:2

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 32 carbons and 2 double bonds.


A sphingomyelin 33:2 obtained by formal condensation of the carboxy group of pentadecanoic acid with the amino group of any sphingadienine-1-phosphocholine.


lysophosphatidylcholine (16:1/0:0)

A lysophosphatidylcholine 16:1 in which the acyl group is located at position 1.


A phosphatidylcholine 38:6 in which the acyl groups specified at positions 1 and 2 are (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl and hexadecanoyl respectively.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 25 carbons and 0 double bonds.


A sphingomyelin d18:1 in which the acyl group specified is tetradecenoyl.


A sphingomyelin in which the total number of carbons in the fatty acyl group is 24 with 1 double bond.


A sphingomyelin 40:2 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of any sphingadienine-1-phosphocholine.


sphingomyelin d18:1/24:1

A sphingomyelin d18:1 in which the fatty acyl group contains 24 carbons and 1 double bond.


A phosphatidylcholine 36:0 where the acyl substituents at positions 1 and 2 are icosanoyl and palmitoyl respectively.


sphingomyelin d18:1

Any sphingomyelin having sphingosine as the sphingoid component.


lysophosphatidylcholine 20:3

A lysophosphatidylcholine in which the acyl group contains 20 carbons with 3 double bonds. If R1 is an acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is an acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.


A phosphatidylcholine 40:6 in which the acyl groups specified at positions 1 and 2 are octadecanoyl and (9Z,11Z,13Z,15Z,17Z,19E)-docosahexaenoyl respectively.


A  phosphatidylcholine 36:4 in which the acyl groups specified at positions 1 and 2 are (6Z,9Z,12Z)-octadecatrienoyl and (9Z)-octadecenoyl respectively.


A sphingomyelin d18:1 in which the acyl group specified is heneicosanoyl.


A phosphatidylcholine 36:2 in which the phosphatidyl acyl groups at positions 1 and 2 are both oleoyl.


phosphatidylcholine P-40:6

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups contain a total of 40 carbon atoms with 6 additional double bonds.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as (9Z)-hexadecenoyl and acetyl respectively.


A phosphatidylcholine 36:3 in which the acyl groups at positions 1 and 2 are specified as octadecadienoyl and octadecenoyl respectively.


A N-hexacosenoylsphingosine-1-phosphocholine consisting of sphingosine as the sphingoid base acylated at the N atom by a (17Z)-hexacosenoyl group.


phosphatidylcholine 32:3

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 3 double bonds.


sn-monothiophosphatidylcholine

A monothioglycerophosphocholine that is an sn-1- or -2-monothioglycero-3-phosphocholine bearing one or two acyl substituents at positions 1 and/or 2.


sphingomyelin d18:1/18:0

A sphingomyelin d18:1 in which the fatty acyl group contains 18 carbons and is fully saturated.


A  1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and linoleoyl (9Z,12Z-octadecadienoyl) respectively.


A phosphatidylcholine 36:6 in which the acyl groups at positions 1 and 2 tetradecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.


phosphatidylcholine (14:0/18:2)

A phosphatidylcholine 32:2 in which the fatty acyl groups at positions 1 and 2 are specified as C14:0 and C18:2 respectively.


phosphatidylcholine O-40:4

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 4 double bonds.


sphingomyelin 24:1

A sphingomyelin in which the total number of carbons contained in the sphingoid base and fatty acyl groups is 24 with 1 double bond.


phosphatidylcholine 28:6

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 28 carbons in total with 6 double bonds.


A 2-acyl-sn-glycero-3-phosphocholine obtained by formal condensation of one of the carboxy groups of azelaic acid with the 1-hydroxy group of sn-glycero-3-phosphocholine.


A phosphatidylcholine 38:4 in which the two acyl substituents at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.


A phosphatidylcholine 27:0 in which the acyl groups at positions 1 and 2 are specified as octadecanoyl and nonanoyl respectively.


A glycerophosphocholine that is glycero-3-phosphocholine carrying unspecified alk-1-enyl and acyl groups at positions 1 and 2 respectively. Major species at pH 7.3.


A 2-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as hexadecyl.


phosphatidylcholine 32:6

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 6 double bonds.


phosphatidylcholine 13:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 13 carbons and no double bonds.


A  phosphatidylcholine 34:2 in which the acyl groups specified at positions 1 and 2 are (9Z,12Z)-octadecadienoyl and linoleoyl respectively.


A phosphatidylcholine O-36:1 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and (9Z)-eicosenoyl respectively.


A 1-O-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as pentadecanoyl.


A lysophosphatidylcholine 18:2 in which the acyl group at position 1 is (9Z,12Z)-octadecadienoyl.


A 1-O-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as icosanoyl.


A lysophosphatidylcholine 20:1 in which the acyl group is located at position 1.


phosphatidylcholine 42:6

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 42 carbons in total with 6 double bonds.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 21 carbons and 0 double bonds and is 2-hydroxylated.


An N-acylsphinganine-1-phosphocholine in which the ceramide N-acyl group is specified as nonadecanoyl.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the 1- and 2-acyl groups are specified as hexadecanoyl and 9-oxononanoyl respectively.


lysophosphatidylcholine 19:1

A lysophosphatidylcholine in which the remaining acyl group (position unspecified) contains 19 carbons and 1 double bond.


A phosphatidylcholine 36:5 in which the acyl groups specified at positions 1 and 2 are hexadecanoyl and (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl respectively.


A phosphosphingolipid that is 15-methylhexadecasphing-4-enine substituted at position 1 by a phosphocholine moiety


sphingomyelin 38:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 38 with 1 double bond.


A 1-oleoyl-2-acyl-sn-glycero-3-phosphocholine in which the acyl substituent at position 2 is specified as acetyl.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 21 carbons and 4 double bonds and is 2-hydroxylated.


phosphatidylcholine 44:5

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 5 double bonds.


A sphingomyelin 42:2 obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of any sphingadienine-1-phosphocholine.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 22 carbons and 1 double bond.


phosphatidylcholine O-40:0

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 0 double bonds.


A phosphatidylcholine O-34:2 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and [(9Z,12Z)-octadecadienoyl respectively.


A phosphatidylcholine 32:2 in which the acyl groups specified at positions 1 and 2 are tetradecanoyl and (9Z,12Z)-octadecadienoyl respectively.


phosphatidylcholine (17:0/20:4)

A phosphatidylcholine 37:4 in which the fatty acyl groups at positions 1 and 2 are specified as C17:0 and C20:4 respectively.


phosphatidylcholine 35:4

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 35 carbons in total with 4 double bonds.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 26 carbons and 2 double bonds.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as hexadecanoyl and (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl respectively.


A sphingomyelin obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 14-methylhexadecasphinganine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.


phosphatidylcholine (16:1/18:1)

A phosphatidylcholine 34:2 in which the fatty acyl groups at positions 1 and 2 are specified as C16:1 and C18:1 respectively.


A phosphatidylcholine 36:5 in which the acyl groups specified at positions 1 and 2 are (9Z)-hexadecenoyl and (5Z,8Z,11Z,14Z)-eicosatetraenoyl respectively.


sphingomyelin 44:0

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 44 with 0 double bonds.


A sphingomyelin 43:2 obtained by formal condensation of the carboxy group of any tetracosenoic acid with the amino group of nonadecasphingosine-1-phosphocholine.


A 1,2-diacyl-sn-glycero-3-phosphocholine where the acyl groups at positions 1 and 2 are palmitoyl and icosanoyl respectively.


phosphatidylcholine (16:0/22:6)

A phosphatidylcholine 38:6 in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C22:6 respectively.


A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and 4-hydroxybutyl respectively.


phosphatidylcholine P-34:3

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups contain a total of 34 carbon atoms with 3 additional double bonds.


A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphocholine in which the alkenyl group is (1Z,9Z)-octadecadienyl.


phosphatidylcholine 26:2

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 26 carbons in total with 2 double bonds.


Major microspecies at pH 7.3.


sphingomyelin 22:0

A sphingomyelin in which the total number of carbons contained in the sphingoid base and fatty acyl groups is 22 with zero double bonds.


flutropium

A carboxylic ester resulting from the formal condensation of the carboxy group of hydroxy(diphenyl)acetic acid with the hydroxy group of (3-endo,8-syn)-8-(2-fluoroethyl)-3-hydroxy-8-methyl-8-azoniabicyclo[3.2.1]octane. Its bromide salt is used as a drug for the treatment asthma and chronic obstructive pulmonary disease.


phosphatidylcholine 35:2

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 35 carbons in total with 2 double bonds.


sphingomyelin 43:7

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 43 with 7 double bonds.


A phosphatidylcholine 24:0 in which the acyl groups specified at positions 1 and 2 are undecanoyl and tridecanoyl respectively.


1-acyl-2-palmitoyl-sn-glycero-3-phosphocholine in which the 1-acyl group is specified as heptanoyl.


A phosphatidylcholine 34:0 in which the two acyl substituents at positions 1 and 2 are specified as stearoyl and palmitoyl respectively.


phosphatidylcholine 44:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 0 double bonds.


sphingomyelin 44:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 44 with 1 double bond.


A sphingomyelin 39:1 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 15-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl substituents at positions 1 and 2 are specified as stearoyl and acetyl respectively.


lysophosphatidylcholine O-17:0

A monoalkyl-sn-glycero-3-phosphocholine in which the alkyl group (position not specified) contains 17 carbons and is fully saturated.


lysophosphatidylcholine 14:1(9Z)/0:0

A lysophosphatidylcholine 14:1 in which the remaining acyl group is (9Z)-tetradecenoyl.


A 1,2-diacyl-sn-glycero 3-phosphocholine in which the acyl group at position 1 is unspecified while that at position 2 is specified as (S)-12-hydroxyoleoyl.


(R)-bethanechol

The (R)-enantiomer of bethanechol.


A lysophosphatidylcholine 18:1 in which the acyl group specified as position 1 is (11Z)-octadecenoyl.


A sphingomyelin in which the sphingoid component is specified as tetradecasphinganine.


A phosphatidylcholine 36:0 in which the acyl groups at positions 1 and 2 are tetradecanoyl and docosanoyl respectively.


A phosphatidylcholine O-40:6 in which the alkyl and the acyl groups at positions 1 and 2 are octadecyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.


acylcholine

A choline ester formed from choline and a carboxylic acid.


A phosphatidylcholine 28:0 in which the two acyl substituents at positions 1 and 2 are specified as lauroyl and palmitoyl respectively.


A sphingomyelind18:1 in which   the total number of carbons in the fatty acyl group is 26 with 2 double bonds.


An N-hydroxytetracosenoylsphingosine-1-phosphocholine in which the N-acyl group is specified as (15Z)-3-hydroxytetracos-15-enoyl.


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as octanoyl.


name: 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide


A 1-O-acyl-sn-glycero-3-phosphocholine obtained by hydroxylation at position 8 of 1-O-oleoyl-sn-glycero-3-phosphocholine.


A phosphatidylcholine 42:0 in which the acyl groups specified at positions 1 and 2 are octadecanoyl and tetracosanoyl respectively.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 28 carbons and 0 double bonds and is 2-hydroxylated.


A phosphatidylcholine 26:0 in which the two acyl substituents at positions 1 and 2 are palmitoyl and decanoyl respectively.


A sphingomyelin 44:0  in which the N-acyl group and sphingoid base are specified as hexacosanoyl and sphinganine respectively.


phosphatidylcholine 33:2

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 33 carbons in total with 2 double bonds.


phosphatidylcholine O-38:2

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 38 carbons and 2 double bonds.


phosphatidylcholine 44:1-OH

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 1 double bond and 1 hydroxy group.


A sphingomyelin d18:1 in which the ceramide N-acyl group is specified as (11Z)-icosenoyl.


phosphatidylcholine 37:3

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 37 carbons in total with 3 double bonds.


phosphatidylcholine 36:5

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 36 carbons in total with 5 double bonds.


A phosphatidylcholine O-38:2 in which the alkyl and acyl groups specified at positions 1 and 2 are octadecyl and (11Z,14Z)-eicosadienoyl respectively.


An sn-glycero-3-phosphocholine compound having a palmitoyl substituent at the 1-hydroxy position


lysophosphatidylcholine 24:0

A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 24 carbons and 0 double bonds.


A 1-palmitoyl-2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group has 20 carbons and 3 double bonds.


A phosphatidylcholine 37:5 in which the acyl groups at positions 1 and 2 are specified as heptadecenoyl and icosatetraenoyl respectively.


A lysophosphatidylcholine 22:4 in which the acyl group is specified as (7Z,10Z,13Z,16Z)-docosatetraenoyl and is located at position 1.


An sn-monothiophosphatidylcholine in which the acyl substituents at O-1 and S-2 are hexadecyl and hetanoyl respectively; an analogue of diheptanoyl thio-PC that contains an ether-linked saturated C16 moiety at the sn-1 position rather than a heptanoyl thiol ester.


sphingomyelin d18:1/23:3

A sphingomyelin d18:1 in which the total number of carbons in the fatty acyl group is 23 with 3 double bonds.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are pentadecanoyl and (5Z,8Z,11Z,14Z)-eicosatetraenoyl respectively.


A lysophosphatidylcholine 18:1 in which the acyl group is at position 1 is elaidoyl [(9E)-octadec-9-enoyl] and the hydoxy group at position 2 is unsubstituted.


A sphingomyelin 39:1 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of heptadecasphingosine-1-phosphocholine.


phosphatidylcholine (16:1/20:4)

A phosphatidylcholine 36:5 in which the fatty acyl groups at positions 1 and 2 are specified as C16:1 and C20:4 respectively.


A phosphatidylcholine 36:4 in which the acyl groups at positions 1 and 2 are octadecanoyl and (6Z,9Z,12Z,15Z)-octadecatetraenoyl respectively.


A sphingomyelin d18:1 in whihc the acyl group specified is nonadecanoyl.


A glycerophosphocholine that is glycero-3-phosphocholine carrying one alkyl and one acyl group in unspecified positions. Major species at pH 7.3.


A galactose phosphate consisting of N-acetyl-D-galactosamine having a choline phosphate group at the 6-position.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 24 carbons and 0 double bonds and is 2-hydroxylated.


Major species at pH 7.3.


phosphatidylcholine 24:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 24 carbons in total with 0 double bonds.


sphingomyelin 42:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 42 with 1 double bond.


A  phosphatidylcholine 30:0 in which the acyl group specified at positions 1 and 2 is pentadecanoyl.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 17 carbons and 0 double bonds and is 2-hydroxylated.


phosphatidylcholine 15:1

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 15 carbons and 1 double bond.


An N-acylsphinganine-1-phosphocholine obtained by formal condensation of the carboxy group of any octadecenoic acid with the amino group of sphinganine-1-phosphocholine.


A phosphatidylcholine 36:2 in which the acyl groups specified at positions 1 and 2 are octadecanoyl and (2E,4E)-octadecadienoyl respectively.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 24 carbons and 4 double bonds and is 2-hydroxylated.


phosphatidylcholine (18:1/22:6)

A phosphatidylcholine 40:7 in which the fatty acyl groups at positions 1 and 2 are specified as C18:1 and C22:6 respectively.


A N-acylsphinganine-1-phosphocholine in which the acyl group specified is tricosanoyl.


lysophosphatidylcholine 24:1

A lysophosphatidylcholine in which the remaining acyl group (position not specified) contains 24 carbons and 1 double bond.


lysophosphatidylcholine 20:3/0:0

A 1-O-acyl-sn-glycero-3-phosphocholine in which the acyl group at C-1 contains 20 carbons and 3 double bonds.


phosphatidylcholine (18:0/22:5)

A 1,2-diacyl-sn-glycero-3-phosphocholine in which one acyl group has 18 carbons and is fully saturated while the other has 22 carbons and 5 double bonds.


phosphatidylcholine 42:11

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 42 carbons and 11 double bonds.


phosphatidylcholine 44:2-OH

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 2 double bonds and 1 hydroxy group.


A sphingomyelin obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphinganine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.


A phosphatidylcholine 36:2 in which the acyl groups specified at positions 1 and 2 are octadecanoyl and (10Z,12Z)-octadecadienoyl respectively


phosphatidylcholine (22:4/22:6)

A phosphatidylcholine 44:10 in which the fatty acyl groups at positions 1 and 2 are specified as C22:4 and C22:6 respectively.


lysophosphatidylcholine P-18:1/0:0

A lysophosphatidylcholine P-18:1 in which the alkenyl group is located at position 1.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 28 carbons and 0 double bonds.


A sphingomyelin 34:0 in which the N-acyl group and sphingoid base are specified as hexadecanoyl and phytosphingosine respectively.


lysophosphatidylcholine (0:0/18:1)

A lysophosphatidylcholine 18:1 in which the acyl group is located at position 2.


lysophosphatidylcholine 17:1

A lysophosphatidylcholine in which the remaining acyl group contains 17 carbons and 1 double bond. If R1 is acyl and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is acyl then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.


lysophosphatidylcholine 16:2

A lysophosphatidylcholine in which the remaining acyl group contains 16 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.


phosphatidylcholine O-40:2

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 2 double bonds.


lysophosphatidylcholine P-18:3

A 1-O-(alk-1-enyl)-sn-glycero-3-phosphocholine in which the alk-1-enyl group contains 18 carbons and 3 additional double bonds.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 18 carbons and 0 double bonds and is 2-hydroxylated.


phosphatidylcholine O-44:0

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 44 carbons and 0 double bonds.


A phosphatidylcholine 38:0 in which the acyl groups specified at positions 1 and 2 are tetradecanoyl and tetracosanoyl respectively.


phosphatidylcholine 26:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 26 carbons in total with 0 double bonds.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 20 carbons and 1 double bond.


An N-acyl-4-hydroxy-15-methylhexadecasphinganine-1-phosphocholine in which the acyl group has 26 carbons and 0 double bonds and is 2-hydroxylated.


sphingomyelin 28:0

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 28 with 0 double bonds.


A phosphatidylcholine O-38:0 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and docosanoyl respectively.


sphingomyelin 44:2

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 44 with 2 double bonds.


sphingomyelin 30:4

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 30 with 4 double bonds.


A phosphatidylcholine 36:4 in which one acyl group has 16 carbons and is fully saturated while the other has 20 carbons and 4 double bonds (position not specified).


A phosphatidylcholine 26:0 in which the acyl groups at positions 1 and 2 are specified as octadecanoyl and octanoyl respectively.


sphingomyelin 40:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 40 with 1 double bond.


phosphatidylcholine 44:10

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 10 double bonds.


phosphatidylcholine 36:8

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 36 carbons and 8 double bonds.


A lysophosphatidylcholine 18:0 in which the acyl group is specified as stearoyl (octadecanoyl) and is located at position 2.


A phosphatidylcholine 34:1 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 11Z-octadecenoyl (cis-vaccenoyl) respectively.


A sphingomyelin 41:1 in which the N-acyl group and sphingoid base are specified as tricosanoyl and sphingosine respectively.


A phosphatidylcholine 40:5 in which the acyl groups at C-1 and C-2 are octadecanoyl and (4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl respectively.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl substituents at positions 1 and 2 are specified as palmitoyl and acetyl respectively.


phosphatidylcholine 40:8

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 40 carbons in total with 8 double bonds.


A phosphatidylcholine (22:4/20:4) which carries a (6Z,9Z,12Z,15Z)-22-oxodocosa-6,9,12,15-tetraen-22-yl group at position 1 and a (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl group at position 2.


sphingomyelin 44:5

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 44 with 5 double bonds.


An alkylacylglycero-3-phosphocholine in which the alkyl and acyl groups are located at positions 1 and 2 respectively. Major species at pH 7.3.


p-aminophenylphosphocholine

A phosphocholine that is the 4-aminophenyl ester of choline phosphate.


A phosphatidylcholine 30:2 in which the acyl groups specified at positions 1 and 2 are (9Z)-hexadecenoyl and (9Z)-tetradecenoyl respectively.


phosphatidylcholine 38:3

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 38 carbons with 3 double bonds.


A lysophosphatidylcholine 18:2 in which the acyl group is specified as linoleoyl and is located at position 2.


A 1-(alk-1-enyl)-2-oleoyl-sn-glycero-3-phosphocholine in which the alk-1-enyl group has Z geochemistry.


A phosphatidylcholine 24:0 in which the acyl groups specified at positions 1 and 2 are nonanoyl and pentadecanoyl respectively.


phosphatidylcholine O-28:0

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 28 carbons and no double bonds.


A  1-O-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group is (9Z)-hexadecenoyl (palmitoleoyl).


A lysophosphatidylcholine 18:0 in which the acyl substituent is located at position 1 and is specified as stearoyl.


sphingosylphosphocholine acid

A cationic phosphosphingolipid consisting of sphingosine having a phosphocholine moiety attached to its primary hydroxyl group.


A phosphatidylcholine 37:4 in which the acyl substituents at positions 1 and 2 are specified as heptadecanoyl and arachidonoyl respectively.


phosphatidylcholine O-38:4

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 38 carbons and 4 double bonds.


A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and succinyl respectively.


phosphatidylcholine (20:4/22:1)

A phosphatidylcholine 42:5 in which the fatty acyl groups at positions 1 and 2 are specified as C20:4 and C22:1 respectively.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as heptadecanoyl and (9Z,12Z,15Z)-octadecatrienoyl respectively.


A sphingomyelin d18:1 in which the ceramide N-acyl group contains 24 carbons, 1 hydroxy group and 1 double bond.


phosphatidylcholine 10:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 10 carbons and no double bonds.


DIMYRISTOYLPHOSPHATIDYLCHOLINE

A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).


A N-acylsphinganine-1-phosphocholine in which the acyl group specified is (15Z)-tetracosenoyl.


sphingomyelin 35:1

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 35 with 1 double bond.


phosphatidylcholine P-32:1

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups contain a total of 32 carbon atoms with 1 additional double bond.


A phosphatidylcholine 38:0 in which the acyl groups at positions 1 and 2 are specified as eicosanoyl and octadecanoyl respectively.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the phosphatidyl acyl groups at positions 1 and 2 are both arachidonoyl.


sphingomyelin 36:3

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 36 with 3 double bonds.


phosphatidylcholine (16:0/16:1)

A phosphatidylcholine 32:1 in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C16:1 respectively.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 17 carbons and 0 double bonds.


sphingomyelin d18:1/26:1

A sphingomyelin d18:1 in which the fatty acyl group contains 26 carbons and 1 double bond.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 19 carbons and 1 double bond.


phosphatidylcholine 35:0

A phosphatidylcholine in which the two acyl groups contain a total of 35 carbons and no double bonds.


A phosphatidylcholine 34:1 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z-octadecenoyl (oleoyl) respectively.


A 1-acyl-2-alkyl-sn-glycero-3-phosphocholine in which the acyl and alkyl groups at positions 1 and 2 are specified respectively as arachidonoyl and palmityl.


phosphatidylcholine (P-18:0/18:1)

A phosphatidylcholine P-36:1 in which the 1-alk-1-enyl group contains 18 carbons and no additional double bonds while the 2-acyl group contains 18 carbons and 1 double bond.


phosphatidylcholine 12:0

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 12 carbons and no double bonds.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 16 carbons and 0 double bonds and is 2-hydroxylated.


phosphatidylcholine 44:1

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 44 carbons in total with 1 double bond.


phosphatidylcholine O-42:1

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 42 carbons and 1 double bond.


sphingomyelin 38:3

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 38 with 3 double bonds.


(R)-EDELFOSINE

A 1-octadecyl-2-methylglycero-3-phosphocholine that is the (R)-enantiomer of edelfosine.


A sphingomyelin 42:1 obtained by formal condensation of the carboxy group of pentacosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.


azelaoyl-PAF

A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and 8-carboxyoctanoyl respectively.


A phosphatidylcholine 28:0 in which the two acyl substituents at positions 1 and 2 are specified as palmitoyl and lauroyl respectively.


phosphatidylcholine (22:4/20:4)

A phosphatidylcholine 42:8 in which the fatty acyl groups at positions 1 and 2 are specified as C22:4 and C20:4 respectively. The positions of the double bonds are unspecified.


phosphatidylcholine 40:4

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 40 carbons in total and 4 double bonds.


phosphatidylcholine (17:1/18:2)

A phosphatidylcholine 35:3 in which the fatty acyl groups at positions 1 and 2 are specified as C17:1 and C18:2 respectively.


cholines

A quaternary ammonium ion based on the choline ion and its substituted derivatives thereof.


phosphatidylcholine O-35:2

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 35 carbons and 2 double bonds.


A phosphatidylcholine O-36:5 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl respectively.


sphingomyelin 32:0

A sphingomyelin in which the total number of carbons in the sphingoid base and fatty acyl groups is 32 with 0 double bonds.


lysophosphatidylcholine O-18:2

A monoalkylglycerophosphocholine in which the alkyl group contains 18 carbons and 2 double bonds. If R1 is an alkenyl group and R2 is a hydrogen then the molecule is a 1-alkenyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is an alkenyl group then the molecule is a 2-alkenyl-sn-glycero-3-phosphocholine.


An N-hydroxydocosenoylsphingosine-1-phosphocholine in which the N-acyl group is specified as (13Z)-3-hydroxydocos-13-enoyl.


Any 1-acyl-sn-glycero-3-phosphocholine that has an oxidized fatty acyl component. Major species at pH 7.3.


A phosphatidylcholine O-36:0 in which the alkyl and acyl groups specified at positions 1 and 2 are hexadecyl and eicosanoyl respectively.


phosphatidylcholine 39:4

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 39 carbons in total with 4 double bonds.


The ammonium betaine of a 1-O-acyl-sn-glycero-3-phosphocholine arising from deprotonation of the phosphate OH; major species at pH 7.3.


A 1,2-diacyl-sn-glycero-3-phosphocholine in which 1 and 2-acyl groups are specified as palmitoyl (hexadecanoyl) and (10E)-9-hydroperoxyoctadecenoyl respectively.


A phosphatidylcholine 34:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and octadecanoyl (stearoyl) respectively.


A phosphatidylcholine O-42:2 in which the alkyl and acyl groups specified at positions 1 and 2 are icosyl and (13Z,16Z)-docosadienoyl respectively.


A phosphatidylcholine O-32:1 in which the alkyl and acyl groups specified at positions 1 and 2 are tetradecyl and (9Z)-octadecenoyl respectively.


phosphatidylcholine O-34:1

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 34 carbons and 1 double bond.


Major microspecies at pH 7.3.


A sphingomyelin d18:1 in which the N-acyl group is specified as docosanoyl


phosphatidylcholine (18:1/22:2)

A phosphatidylcholine 40:3 in which the fatty acyl groups at positions 1 and 2 are specified as C18:1 and C22:2 respectively.


phosphatidylcholine O-36:1

A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 36 carbons and 1 double bond.


phosphatidylcholine P-40:5

A 1-O-(alk-1-enyl)-2-O-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups at positions 1 and 2 contain 40 carbon atoms in total with 5 additional double bonds.


A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphocholine in which the alk-1-enyl group is specified as (1Z)-octadecenyl.


phosphatidylcholine O-40:3

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 3 double bonds.


lysophosphatidylcholine (22:4/0:0)

A lysophosphatidylcholine 22:4 in which the docosatetraenoyl group is located at position 1.


A 1-octadecanoyl-2-octadecenoyl-sn-glycero-3-phosphocholine in which the acyl groups specified at positions 1 and 2 are (11Z)-octadecenoyl and octadecanoyl respectively.


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 25 carbons and 2 double bonds.


lysophosphatidylcholine 19:2

A lysophosphatidylcholine in which the remaining acyl group (position unspecified) contains 19 carbons and 2 double bonds.


phosphatidylcholine (20:2/20:4)

A phosphatidylcholine 40:6 in which the fatty acyl groups at positions 1 and 2 are specified as C20:2 and C20:4 respectively.


A sphingomyelin  d18:1 in which the ceramide N-acyl group contains 14 carbons, 1 hydroxy group and 1 double bond.


lysophosphatidylcholine 14:1

A lysophosphatidylcholine in which the remaining acyl group contains 14 carbons and 1 double bond. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.


A phosphatidylcholine 34:1 in which one acyl group has 16 carbons and is fully saturated while the other has 18 carbons and 1 double bond (position not specified).


A sphingomyelin in which the sphingoid component is specified as hexadecaphytosphingosine.


phosphatidylcholine O-30:2

An alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 30 carbons and 2 double bonds.


phosphatidylcholine 37:4

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 37 carbons in total with 4 double bonds.


phosphatidylcholine (18:0/22:6)

A phosphatidylcholine 40:6 in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C22:6 respectively.


A sphingomyelin 39:1 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.


1-palmitoyl-2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group is specified as heptanoyl.


phosphatidylcholine 40:6

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain forty carbons in total with six double bonds.


phosphatidylcholine (15:0/16:1)

A phosphatidylcholine 31:1 in which the fatty acyl groups at positions 1 and 2 are specified as C15:0 and C16:1 respectively.


A lysophosphatidylcholine 22:5 in which the acyl group at position 1 is (4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl and the hydroxy group at position 2 is unsubstituted.


A sphingomyelin 34:0 in which the N-acyl group and sphingoid base are specified as hexadecanoyl and sphinganine respectively.


A phosphatidylcholine 24:0 in which the acyl groups specified at positions 1 and 2 are tridecanoyl and undecanoyl respectively.


quaternary ammonium ion

A derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.


name: Lumbar Spine Joint Range of Motion Decreased

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Decreased flexibility of a lumbar spine joint.


A secondary amino compound that is 4-(2-aminoethyl)-2,5-dimethoxybenzonitrile in which one of the hydrogens of the amino group has been replaced by a 2-hydroxybenzyl group. A 5-hydroxytryptamine 2A receptor agonist.


name: Other Atherosclerosis of Native Arteries of Extremities, Bilateral Legs

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Evidence of other atherosclerosis of native arteries of extremities in both legs not specified elsewhere.


Gastric Cancer pT4 TNM Finding v8

description: Gastric cancer with tumor invading the serosa (visceral peritoneum) or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)


name: Gastric Cancer Pathologic TNM Finding v8

description: A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system.


Gastric Cancer pTX TNM Finding v8

description: Gastric cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)


Gastric Cancer pM1 TNM Finding v8

description: Gastric cancer with distant metastasis. (from AJCC 8th Ed.)


Gastric Cancer pT0 TNM Finding v8

description: Gastric cancer with no evidence of primary tumor. (from AJCC 8th Ed.)


Gastric Cancer pT1a TNM Finding v8

description: Gastric cancer with tumor invading the lamina propria or muscularis mucosae. (from AJCC 8th Ed.)


name: Gastric Cancer Pathologic Primary Tumor TNM Finding v8

description: A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.


Gastric Cancer pN2 TNM Finding v8

description: Gastric cancer with metastasis in three to six regional lymph nodes. (from AJCC 8th Ed.)


Gastric Cancer pT2 TNM Finding v8

description: Gastric cancer with tumor invading the muscularis propria. A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified as T4. (from AJCC 8th Ed.)


Gastric Cancer pN1 TNM Finding v8

description: Gastric cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)


Gastric Cancer pT4a TNM Finding v8

description: Gastric cancer with tumor invading the serosa (visceral peritoneum). (from AJCC 8th Ed.)


Gastric Cancer pNX TNM Finding v8

description: Gastric cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)


Gastric Cancer pTis TNM Finding v8

description: Gastric cancer with a finding of carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. (from AJCC 8th Ed.)


name: Gastric Cancer Pathologic Regional Lymph Nodes TNM Finding v8

description: A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.


Gastric Cancer pT4b TNM Finding v8

description: Gastric cancer with tumor invading adjacent structures/organs. (from AJCC 8th Ed.)


Gastric Cancer pT1 TNM Finding v8

description: Gastric cancer with tumor invading the lamina propria, muscularis mucosae, or submucosa. (from AJCC 8th Ed.)


Gastric Cancer pT3 TNM Finding v8

description: Gastric cancer with tumor penetrating the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)


name: Gastric Cancer Pathologic Distant Metastasis TNM Finding v8

description: A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.


Gastric Cancer pT1b TNM Finding v8

description: Gastric cancer with tumor invading the submucosa. (from AJCC 8th Ed.)


Stage IIIB Cervical Cancer FIGO 2018

description: Cervical carcinoma with extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause). (FIGO 2018)


Non-Recurrent Esophageal Carcinoma

description: A finding indicating that a patient with a history of esophageal carcinoma does not have evidence of recurrent disease.


name: Grade 5 Pharynx Stricture or Stenosis, CTCAE


name: Grade 4 Pharynx Stricture or Stenosis, CTCAE


name: Grade 1 Pharynx Stricture or Stenosis, CTCAE


name: Grade 3 Pharynx Stricture or Stenosis, CTCAE


name: Grade 2 Pharynx Stricture or Stenosis, CTCAE


An optically active form of 3-ammonio-3-phenylpropanoate having (S)-configuration.


Leaflet Disruption Due To Calcification

description: The disturbance of a cusp of a heart valve secondary to the accumulation of calcium on the valve tissue. This most often results in stenosis of the valve.


Leaflet Disruption

description: The disturbance of a cusp of a heart valve, often resutling in dysfunction of the valve.


Leaflet Disruption Due To Infection

description: The disturbance of a cusp of a heart valve secondary to infection affecting the valve tissue, which can result in valvular dysfunction.


Leaflet Disruption Due To Unknown Cause

description: The disturbance of a cusp of a heart valve without an identifiable cause.


name: Leaflet Disruption Due To Host Tissue Overgrowth

description: The disturbance of a cusp of a heart valve secondary to an increase in tissue mass at the valve site, which can lead to valve dysfunction. This often happens as a result of fibrosis of tissue surrounding the suture line of a prosthetic valve.


name: Leaflet Disruption Due To Suture Abrasion

description: The disturbance of a cusp of a heart valve secondary to irritation by surgical sutures, which can result in valvular dysfunction.


Colorectal Cancer pT3 a/b TNM Finding

description: Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues, with tumor extension of 5 mm or less beyond the border of the muscularis propria. (from CAP Colorectal Cancer Protocol-January 2005 Revision)


Colorectal Cancer pT3 TNM Finding v6

description: Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues. (from AJCC 6th Ed.)


Colorectal Cancer pT3 c/d TNM Finding

description: Colorectal cancer with invasion through the muscularis propria into the submucosa, or into non-peritonealized pericolic or perirectal soft tissues, with tumor extension of more than 5 mm beyond the border of the muscularis propria. (from CAP Colorectal Cancer Protocol-January 2005 Revision)


Vulvar Fibroadenoma

description: A benign epithelial-stromal neoplasm that arises from the vulva and resembles the breast fibroadenoma.


name: Fibroadenoma of Anogenital Mammary-Type Glands

description: A benign epithelial-stromal neoplasm that arises from the perineum and resembles the breast fibroadenoma.


Anal Fibroadenoma

description: A benign epithelial-stromal neoplasm that arises from the anus and resembles the breast fibroadenoma.


name: Esophageal Squamous Intraepithelial Neoplasia

description: A lesion in which the architectural and cytologic abnormalities involve either the lower or both the lower and the upper half of the esophageal squamous epithelium.


name: High Grade Esophageal Squamous Intraepithelial Neoplasia

description: A lesion in which the architectural and cytologic abnormalities involve both the lower and the upper half of the esophageal squamous epithelium.


name: Low Grade Esophageal Squamous Intraepithelial Neoplasia

description: A lesion in which the architectural and cytologic abnormalities are confined to the lower half of the esophageal squamous epithelium.


name: Extramedullary Disease in Multiple Myeloma Involving the Liver

description: Infiltration of the hepatic sinusoids by malignant (clonal) plasma cells in patients with history of multiple myeloma.


L-ARABINOSE

A L-arabinopyranose with an alpha-configuration at the anomeric position.


ganglioside GM2 (24:1)

A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is tetracos-15-enoyl. A constituent of natural ganglioside GM2.


Grade 4 Cecal Infection, CTCAE

description: Life-threatening consequences; urgent intervention indicated


fisetin 8-C-glucoside

A  flavone C-glycoside that is fisetin substituted by a beta-D-glucopyranosyl residue at position 8 via a C-glycosidic linkage.


name: Malignant Neoplasm of Right Spermatic Cord

description: Evidence of a malignant neoplasm of the right spermatic cord.


name: Chronic Post-Rheumatic Arthropathy, Unspecified Elbow

description: Evidence of chronic post-rheumatic arthropathy in an unspecified elbow.


A 5-HETrE consisting of (6E,8Z,11Z)-icosatrienoic acid in which the 5-hydroxy group has S-configuration.


Grade 1 Urostomy Leak, CTCAE

description: Asymptomatic diagnostic finding; intervention not indicated


name: Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v7

description: High blood tumor burden: 1000/microL Sezary cells or more with positive clone.  Note 1: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei.  If Sezary cells are not able to be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26.  Note 2: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene.  (from AJCC 7th Ed.)


name: Malignant Neoplasm of Unspecified Part of Right Bronchus or Lung

description: Evidence of a malignant neoplasm of an unspecified part of right bronchus or lung.


Grade 3 Lipohypertrophy, CTCAE

description: Covering >30% BSA and associated tenderness and narcotics or NSAIDs indicated; lipohypertrophy; limiting self care ADL


name: Unresectable Diffuse Midline Glioma, H3 K27M-Mutant

description: Diffuse midline glioma, H3 K27M-mutant that is not amenable to surgical resection.


Unresectable Diffuse Midline Glioma

description: Diffuse midline glioma that is not amenable to surgical resection.


Percentage Body Weight Gain

description: The amount of weight gained over a period of time in relation to the total weight.


The alpha-stereoisomer of isoorientin 2''-O-rhamnoside . It has been isolated from Petrorhagia velutina.


CTPB

A benzamide obtained by formal condensation of the carboxy group of 2-ethoxy-6-pentadecylbenzoic acid with one of the amino groups of 4-chloro-3-(trifluoromethyl)aniline.


A secondary amino compound that is ammonia in which nitrogen is substituted by a 1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl group and a 2-(2-ethoxyphenoxy)ethyl group.


ent-tamsulosin

A 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide that has (S)-configuration. The enantiomer of tamsulosin.


name: Stage IIIA Gastric Gastrointestinal Stromal Tumor

description: Stage IIIA includes: T3, N0, M0, Mitotic rate: High. T3: Tumor more than 5 cm, but not more than 10 cm, in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: Long-Term Effects Secondary to Cancer Therapy in Adults

description: Side effects of cancer treatment received during adulthood occurring a long time after the treatment was completed.


Hemangioendothelioma, benign

description: A benign vascular proliferation characterized by the presence of prominent endothelial cells and the formation of vascular channels.


A tricarboxylic acid that is the 2-oxo derivative of homocitric acid.


A 2-hydroxy-4-oxobutane-1,2,4-tricarboxylic acid that has S configuration.


alvaradoin K

A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage  (the 10R stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.


Grade 3 Mania, CTCAE

description: Severe manic symptoms (e.g., hypomania; major sexual or financial indiscretions); hospitalization not indicated; new onset


Mania, CTCAE

description: A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.


Grade 4 Mania, CTCAE

description: Life-threatening consequences, threats of harm to self or others; hospitalization indicated


Grade 2 Mania, CTCAE

description: Moderate manic symptoms (e.g., relationship and work difficulties; poor hygiene)


Grade 1 Mania, CTCAE

description: Mild manic symptoms (e.g., elevated mood, rapid thoughts, rapid speech, decreased need for sleep)


Grade 5 Mania, CTCAE

description: Death


name: Stage IIIA Rectal Neuroendocrine Tumor AJCC v8

description: Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Colorectal Neuroendocrine Tumor by AJCC v8 Stage

description: A term that refers to the staging of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colorectal "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon and rectum are not staged using this staging system. (from AJCC 8th Ed.)


name: Stage I Colorectal Neuroendocrine Tumor AJCC v8

description: Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IIB Colon Neuroendocrine Tumor AJCC v8

description: Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IIB Rectal Neuroendocrine Tumor AJCC v8


name: Stage IIIB Colon Neuroendocrine Tumor AJCC v8

description: Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IIIB Rectal Neuroendocrine Tumor AJCC v8


name: Rectal Neuroendocrine Tumor by AJCC v8 Stage

description: A term that refers to the staging of a rectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to rectal "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the rectum are not staged using this staging system. (from AJCC 8th Ed.)


name: Stage IIB Colorectal Neuroendocrine Tumor AJCC v8


name: Stage IIA Colorectal Neuroendocrine Tumor AJCC v8

description: Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: Stage IIA Rectal Neuroendocrine Tumor AJCC v8


name: Colon Neuroendocrine Tumor by AJCC v8 Stage

description: A term that refers to the staging of a colon neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colon "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon are not staged using this staging system. (from AJCC 8th Ed.)


name: Stage IIIB Colorectal Neuroendocrine Tumor AJCC v8


name: Stage I Colon Neuroendocrine Tumor AJCC v8


name: Stage IIIA Colon Neuroendocrine Tumor AJCC v8


name: Stage IIA Colon Neuroendocrine Tumor AJCC v8


name: Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8


Non-Rheumatic Pulmonary Valve Stenosis

description: Evidence of non-rheumatic pulmonary valve stenosis.


A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 12alpha-hydroxy-3-oxochola-4,6-dien-24-oic acid.


An alpha-D-galactoside that is the 2-aminoethyl glycoside of a tetrasaccharide consisting of beta-D-glucuronosyl, beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues linked sequentially (1->4).


alpha-D-galactoside

Any D-galactoside having alpha-configuration at its anomeric centre.


6-bromo-2-naphthyl alpha-D-galactoside

An alpha-D-galactoside having a 6-bromo-2-naphthyl substituent at the anomeric position.


fagopyritol B1

An alpha-D-galactoside that is 1D-chiro-inositol having an alpha-D-galactosyl residue attached at position 2 via a glycosidic linkage.


An alpha-D-glucoside that is the 2-aminoethyl glycoside of a tetrasaccharide consisting of two beta-D-glucosyl residues, an alpha-D-glucosyl residue and (at the reducing end) an alpha-D-galactosyl residue, all linked sequentially (1->4).


An alpha-D-glucoside that is the 2-aminoethyl glycoside of a pentasaccharide consisting of  alpha-D-galactosyl, beta-D-glucuronosyl, beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues, all linked sequentially (1->4).


An amino disaccharide that is 2-acetamido-2-deoxy-beta-D-glucopyranose in which the hydroxy group at position 3 has been converted into the corresponding alpha-D-galactopyranoside.


A glycosyl glycoside consisting of two alpha-D-galactopyranose residues joined by a (1->1) glycosidic bond.


A glycosyl glycoside that is alpha-D-galactopyranose in which the anomeric hydroxy group has been converted into the corresponding alpha-D-glucopyranosyl derivative.


A fatty amide resulting from the formal condensation of the carboxy group of cerotic acid with the amino group of (2S,3S,4R)-2-aminononane-1,3,4-triol and in which the primary hydroxy group of the resulting product has been converted to the corresponding alpha-D-galactopyranoside.


A disaccharide that is D-glucopyranose in which the hydroxy group at position 2 has been converted into the corresponding alpha-D-galactopyranoside.


An alpha-D-galactoside having a 4-methylumbelliferyl substituent at the anomeric position


An alpha-D-glucoside that is the 2-aminoethyl glycoside of a hexasaccharide consisting of alpha-D-glucosyl, alpha-D-galactosyl, beta-D-glucuronosyl, beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues, all linked sequentially (1->4).


A disaccharide that is L-fucopyranose in which the hydroxy group at position 4 has been converted into the corresponding alpha-D-galactopyranoside.


adxanthromycin A

An organic peroxide, which is the 3-alpha-D-galactopyranosyl substituted derivative of the dimer obtained by oxidation at the 10-hydroxy position of (10S)-3,8,10-trihydroxy-1,7,10-trimethyl-9-oxo-9,10-dihydroanthracene-2-carboxylic acid. It is isolated from the fermentation broth of Streptomyces.


An amino pentasaccharide consisting of alpha-L-fucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-galactopyranose, and 2-acetamido-2-deoxy-beta-D-glucopyranose joined in sequence by (1->4), (1->3), and (1->4) glycosidic bonds and in which the hydroxy group at position 3 of the non-terminal 2-acetamido-2-deoxy-beta-D-glucopyranose moiety has been to the corresponding alpha-D-galactopyranoside.


4-nitrophenyl alpha-D-galactoside

An alpha-D-galactopyranoside having a 4-nitrophenyl substituent at the anomeric position.


An alpha-D-Galp-(1->4)-D-Glcp in which the carbon bearing the anomeric hydroxy group has beta configuration.


A carboxylic ester obtained by formal condensation of 9-(alpha-D-galactosyloxy)nonanoic acid and methanol.


A alpha-D-Galp-(1->4)-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha configuration.


isofloridoside

A galactosylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding alpha-D-galactopyranoside.


A isofloridoside in which position 2 of the glyceryl moiety has R configuration.


A glycosylglucose that is D-glucopyranose in which the hydroxy group at position 4 has been converted into the corresponding alpha-D-galactoside.


A cyclitol ether that is D-myo-inositol carrying methyl and alpha-D-galactosyl substituents at positions 4 and 3 respectively.


A disaccharide that is D-mannitol in which the hydroxy group at position 2 has been converted into its alpha-D-galactopyranoside


An alpha-D-glucoside that is the 2-aminoethyl glycoside of a trisaccharide consisting of  beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues linked sequentially (1->4).


An alpha-D-Galp-(1->2)-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha configuration.


An amino disaccharide that is 2-acetamido-beta-D-glucopyranose in which the hydroxy group at position 6 has been glycosylated by an alpha-D-galactopyranosyl group.


An alpha-D-galactoside having a 1D-myo-inositol substituent at the anomeric position.


fagopyritol A1

An alpha-D-galactoside having a 1D-chiro-inositol substituent at the anomeric position.


A secondary fatty alcohol that is tetradecane substituted by a hydroxy group at position 6.


name: Grade 1 Cardiac Disorders - Other, Specify, CTCAE

description: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated


name: Cardiac Disorders - Other, Specify, CTCAE


name: Grade 2 Cardiac Disorders - Other, Specify, CTCAE

description: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL


name: Grade 5 Cardiac Disorders - Other, Specify, CTCAE

description: Death


name: Grade 3 Cardiac Disorders - Other, Specify, CTCAE

description: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL


name: Grade 4 Cardiac Disorders - Other, Specify, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Pregnancy with Intrauterine Device

description: Co-existence of an intrauterine pregnancy with an intrauterine device.


Menstruation

description: The normal physiologic discharge through the vagina of blood and mucosal tissues from the nonpregnant uterus.


Eroded and Ulcerated Lesion

description: A finding of both erosion and ulceration in the same lesion.


A dTDP-sugar having 3,4-didehydro-2,6-dideoxy-alpha-D-glucose as the sugar component.


name: Thoracoabdominal Aortic Aneurysm, without Rupture

description: Evidence of thoracoabdominal aortic aneurysm, without rupture.


An amino acid zwitterion resulting from the transfer of a proton from the carboxy to the side-chain amino group of any N(2)-[(3R)-hydroxy-acyl]-L-ornithine; major species at pH 7.3.


Breast Cancer pN1mi TNM Finding v7

description: Breast cancer with micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm) (from AJCC 7th Ed.)


A dicarboxylic acid monoamide obtained by formal condensation of the 6-amino group of 2,6-diaminobenzimidazole with one of the carboxy groups of glutaric acid.


triphenylmethane

A triarylmethane in which the three aryl groups are phenyl. It forms the basic skeleton of several synthetic dyes.


triarylmethane

Any benzenoid aromatic compound containing three aryl groups connected by a single C atom.


name: Head and Neck Phosphaturic Mesenchymal Tumor

description: A phosphaturic mesenchymal tumor that arises from the head and neck. It usually affects the paranasal sinuses. The head and neck region is the most frequently involved site for phosphaturic mesenchymal tumors, following the appendicular skeleton.


name: Appendicular Skeleton Phosphaturic Mesenchymal Tumor

description: A phosphaturic mesenchymal tumor that arises from the appendicular skeleton. The appendicular skeleton is the most frequently involved site for phosphaturic mesenchymal tumors.


name: Malignant phosphaturic mesenchymal tumor

description: A phosphaturic mesenchymal tumor characterized by the presence of nuclear atypia, high mitotic activity, increased cellularity, marked pleomorphism, and necrosis. It usually develops in lesions that have recurred locally and metastasizes to other sites.


A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups.


A FAHFA obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 11-hydroxystearic acid.


Left Cardiac Artery Dominance

description: The posterior descending artery (PDA) and posterolateral artery (PLA) arises from the left circumflex artery. (ACC)


D-glycero-D-manno-heptose 7-phosphate

D-glycero-D-manno-heptose in which the hydrogen of the primary hydroxy group is substituted by a dihydrogen phosphate group.


The 1-alpha-anomer of D-glycero-D-manno-heptose 7-phosphate.


D-glycero-beta-D-manno-heptose in which the hydrogens of the hydroxy groups at positions 1 and 7 are substituted by dihydrogen phosphate groups.


Dianion of D-glycero-D-manno-heptose 1-phosphate arising from deprotonation of both phosphate OH groups.


D-glycero-D-manno-heptose 1-phosphate(2-) with alpha-configuration at the anomeric carbon atom.


D-glycero-D-manno-heptose 1-phosphate(2-) with beta-configuration at the anomeric carbon atom.


D-glycero-alpha-D-manno-heptose in which the hydrogens of the hydroxy groups at positions 1 and 7 are substituted by dihydrogen phosphate groups.


The 1-beta-anomer of D-glycero-D-manno-heptose 7-phosphate.


D-glycero-D-manno-heptose in which the hydrogens of the hydroxy groups at positions 1 and 7 are substituted by dihydrogen phosphate groups.


A hydroxyaldehyde that is pentanal carrying three hydroxy substituents at positions 3, 4 and 5.


name: Metastatic malignant neoplasm to trachea

description: A malignant neoplasm that has spread to the trachea from another anatomic site.


name: Type 2 Diabetes Mellitus with Moderate Nonproliferative Diabetic Retinopathy without Macular Edema, Right Eye

description: Evidence of type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema in the right eye.


Sarcoma of the Orbit pM1 TNM Finding v7

description: Sarcoma of the orbit with distant metastasis. (from AJCC 7th Ed.)


GlyTouCan G08691QG

A composition-only glycan consisting of four hexosyl groups, one acetaminohexosyl group and two 6-deoxyhexosyl groups (identities and connectivity unknown). Composition: Hex4 HexNAc1 dHex2.


GlyTouCan G00406II

A composition-only glycan consisting of four hexosyl groups, two acetaminohexosyl groups, and one 6-deoxyhexosyl group (identities and connectivity unknown). Composition: Hex4 HexNAc2 dHex1.


GlyTouCan G05194RK

A composition-only glycan consisting of three hexosyl groups, two acetaminohexosyl groups and two N-acetyl-neuraminic acid group (identities and connectivity unknown). Composition: Hex3 HexNAc2 NeuAc2.


GlyTouCan G05645NK

A composition-only glycan consisting of six hexosyl groups and one acetaminohexosyl group (identities and connectivity unknown). Composition: Hex6 HexNAc1.


GlyTouCan G04371QE

A composition-only glycan consisting of four hexosyl groups, two acetaminohexosyl groups and one N-acetyl-neuraminic acid group (identities and connectivity unknown). Composition: Hex4 HexNAc2 NeuAc1.


GlyTouCan G02815KT

A partially-defined glycan consisting of 5 hexosyl and 2 acetaminohexosyl groups (identities and connectivity unknown). Composition: Hex5 HexNAc2.


GlyTouCan G06110VR

An aminoheptasaccharide consisting of five hexosyl and two acetaminohexosyl groups (identities and connectivity unknown). Composition: Hex5 HexNAc2.


An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched heptasaccharide consisting of alpha-D-glucuronosyl, beta-D-mannosyl, alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->3), (1->4), (1->3), (1->4) and (1->4), to the mannosyl residue proximal to the reducing end of which has also linked (1->3) to it an alpha-D-glucuronosyl residue. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.


GlyTouCan G03666XN

A composition-only glycan consisting of five hexosyl groups, one 2-acetaminohexosyl group and one 6-deoxyhexosyl group (identities and connectivity unknown). Composition: Hex5 HexNAc1 dHex1.


Grade 1 Ejaculation Disorder, CTCAE

description: Diminished ejaculation


Ejaculation Disorder, CTCAE

description: A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.


Grade 2 Ejaculation Disorder, CTCAE

description: Anejaculation or retrograde ejaculation


name: Grade 4 Trachea Mucositis or Stomatitis by Clinical Examination Classification, CTCAE


Fetal Engagement

description: A position adopted by the fetus during labor when its head moves down into the maternal pelvic cavity.


icosa-5,8,12,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 8, 12 and 14.


icosatetraenoic acid

A 20-carbon, polyunsaturated fatty acid having four double bonds at unspecified positions.


icosa-5,8,11,13-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 13.


all-cis-8,11,14,17-icosatetraenoic acid

An icosatetraenoic acid having four cis double bonds at positions 8, 11, 14 and 17.


(5Z,8Z,10E,12E)-icosatetraenoic acid

An icosatetraenoic acid in which the four double bonds are located at positions 5, 8, 10 and 12 (the 5Z,8Z,10E,12E-isomer).


icosa-5,8,10,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 8, 10 and 14.


icosa-6,8,10,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 6, 8, 10 and 14.


icosa-5,7,11,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 7, 11 and 14.


icosa-7,9,11,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 7, 9, 11 and 14.


icosa-5,9,11,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 9, 11 and 14.


(5Z,11Z,14Z,17Z)-icosatetraenoic acid

An icosatetraenoic acid in which the four double bonds have Z configuration and are located at positions 5, 11, 14 and 17.


icosa-6,8,11,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 6, 8, 11 and 14.


icosa-5,8,11,14-tetraenoic acid

Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.


(R)-tetraconazole

A 1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]1,2,4-triazole that is the (R)-enantiomer of tetraconazole.


(S)-tetraconazole

A 1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]1,2,4-triazole that is the (S)-enantiomer of tetraconazole.


name: Bilateral Synchronous Sporadic Renal Cell Carcinoma

description: Non-hereditary renal cell carcinoma arising from a kidney and detected in the other kidney within six months of the first primary. The majority are clear cell renal cell carcinomas.


Kidney Germ Cell Tumor

description: A rare benign or malignant germ cell tumor that arises from the kidney.


name: Unspecified viral hepatitis without hepatic coma

description: Evidence of unspecified viral hepatitis without hepatic coma.


Grade 3 Sinus Pain, CTCAE

description: Severe pain; limiting self care ADL


MAGNESIUM CHLORIDE

A hydrate that is the hexahydrate form of magnesium dichloride.


name: Vulvar Cancer Pathologic Primary Tumor TNM Finding v7

description: A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.


Vulvar Cancer pT0 TNM Finding v7

description: Vulvar cancer with no evidence of primary tumor. (from AJCC 7th Ed.)


Vulvar Cancer pT2 TNM Finding v7

description: Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement). (from AJCC 7th Ed.)


Vulvar Cancer pT1 TNM Finding v7

description: Invasive vulvar cancer confined to the vulva or perineum. (from AJCC 7th Ed.)


Vulvar Cancer pT1b TNM Finding v7

description: Vulvar cancer with tumor size greater than 2 cm, or any size with stromal invasion more than 1.0 mm, confined to the vulva or perineum. (from AJCC 7th Ed.)


Vulvar Cancer pT3 TNM Finding v7

description: Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal 2/3 urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone. (from AJCC 7th Ed.)


Vulvar Cancer pT1a TNM Finding v7

description: Vulvar cancer with tumor size 2 cm or less, confined to the vulva or perineum and with stromal invasion 1.0 mm or less.  The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.  (from AJCC 7th Ed.)


Vulvar Cancer pTX TNM Finding v7

description: Vulvar cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)


Vulvar Cancer pTis TNM Finding v7

description: Vulvar cancer with a finding of carcinoma in situ. (from AJCC 7th Ed.)


Arteriovenous graft thrombosis

description: Partial or complete occlusion of the lumen of an arteriovenous graft by a thrombus.


A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxochenodeoxycholic acid.


name: Type 1 Diabetes Mellitus with Proliferative Diabetic Retinopathy with Combined Traction Retinal Detachment and Rhegmatogenous Retinal Detachment, Left Eye

description: Evidence of type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment in the left eye.


Grade 5 Epistaxis, CTCAE

description: Death


calixfurans

Compounds containing a calixfuran skeleton.


calixfuran

A macrocycle composed of furan-2,5-diyl groups linked by methylene groups. The number of furan-2,5-diyl units in the macrocycle is denoted by the "n" in calix[n]furan name.


Grade 3 Trismus, CTCAE

description: Decreased ROM with inability to adequately aliment or hydrate orally


name: Refractory Childhood Acute Lymphoblastic Leukemia

description: Acute lymphoblastic leukemia that occurs in childhood and does not respond to treatment.


name: Cutaneous Melanoma cM1a(1) TNM Finding v8

description: Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level elevated. (from AJCC 8th Ed.)


Childhood Acute Basophilic Leukemia

description: An acute basophilic leukemia occurring in children.


A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl and octadecanoyl respectively.


Sinonasal Solitary Fibrous Tumor

description: A solitary fibrous tumor that arises from the nasal cavity and paranasal sinuses.


HIRSUTELLIDE A

A cyclodepsipeptide isolated from the cell extract of the entomopathogenic fungus Hirsutella kobayasii BCC 1660 and exhibits antimycobacterial and antimalarial activities.


Supernumerary Hemivertebra

description: More than the usual or expected number of hemivertebra.


(R)-glycol nucleic acid

Glycol nucleic acids with an (R) chiral centre in the glycol backbone. They can be synthetically derived from (R)-(+)-glycidol.


organic vanadium salt

A vanadium salt with C-H bonds


A member of the class of phenylureas that is urea in which one of the nitrogens bears a 3-tert-butyl-1-[(3S)-3-carboxy-1,2,3,4-tetrahydroisoquinolin-6-yl]-1H-pyrazol-5-yl substituent, while the other bears a 2,3-dichlorophenyl group.


A 3beta-hydroxy steroid that is cathasterone which is lacking the oxo substituent at position 6.


A diiodotyrosine that is L-tyrosine carrying iodo-substituents at positions C-3 and C-5 of the benzyl group. It is an intermediate in the thyroid hormone synthesis.


name: Malignant neoplasm of hypopharynx recurrent

description: The reemergence of a hypopharyngeal malignant neoplasm after a period of remission.


Benign neoplasm of pyriform sinus

description: A neoplasm that arises from the pyriform sinus and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.


Neoplasm of pyriform sinus

description: A benign or malignant neoplasm that affects the pyriform sinus.


T1c TNM Finding

description: A general term that refers to a TNM finding of a primary tumor limited to the site of growth.  The definition of T1c TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to a primary tumor that is more than 1.0 cm, but not more than 2.0 cm in greatest dimension; for uterine corpus cancer it refers to a primary tumor that invades one-half or more of the myometrium; and for melanoma of the iris it refers to a primary tumor limited to the iris with secondary glaucoma.


COVID-19-Associated Anosmia

description: Anosmia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).


A N-acylglycine that is glycine substituted by a 2-methylbutanoyl group at the N atom.


name: Grade 3 Appendix Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Appendix Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 2 Appendix Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 5 Appendix Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 4 Appendix Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Pauciarticular Juvenile Rheumatoid Arthritis, Left Ankle and Foot

description: Evidence of pauciarticular juvenile rheumatoid arthritis in the left ankle and foot.


A steroid acid that is 5beta-cholestan-26-oic acid which is substituted by hydroxy groups as the 3alpha, 7alpha, and 12alpha positions.


name: Initiation of Pharyngeal Swallow with Bolus Head at Posterior Laryngeal Surface of Epiglottis

description: A finding of pharyngeal swallow initiated with bolus head at posterior laryngeal surface of epiglottis.


name: Soft Tissue Sarcoma of the Trunk and Extremities pN1 TNM Finding v8

description: Soft tissue sarcoma of the trunk and extremities with regional lymph node metastasis. (from AJCC 8th Ed.)


name: 3,3-Dimethyl allyl-p-propenyl phenyl ether


Tentorial tear due to birth trauma

description: Pertaining to tears involving the tentorium of the cerebellum.


name: Colorectal Neuroendocrine Tumor pT3 TNM Finding v8

description: Colorectal neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)


name: Grade 4 Stoma Pulmonary Hemorrhage, CTCAE


An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,11Z,14Z,17Z)-icosatetraenoic acid.


Change in Emotional State

description: Change from the affected person's usual emotional state.


A heteroarenecarbaldehyde that is indole in which the hydrogen at position 4 has been replaced by a formyl group.


LEHUALIDE F

A member of the class of 2-pyranones that is 2H-pyran-2-one substituted by a methoxy group at position 3, a hydroxy group at position 4, a methyl group at position 5 and a (2E)-3-methyl-9-phenylnon-2-en-1-yl group at position 6. Isolated from the marine sponge of the genus Plakortis, it exhibits cytotoxicity against human promyeloid leukemic HL-60 cells.


mycinamicin VI

A mycinamicin composed of a 16-membered ring macrolactone core, an N,N-dimethylated deoxysugar desosamine and a 6-deoxysugar 6-deoxyallose.


Resectable Carcinoma

description: Carcinoma that is amenable to surgical resection.


name: Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: Cutaneous squamous cell carcinoma of the head and neck that is amenable to surgical resection.


Resectable Periampullary Adenocarcinoma

description: Periampullary adenocarcinoma that is amenable to surgical removal.


name: Resectable Liver and Intrahepatic Bile Duct Carcinoma

description: Liver carcinoma that is amenable to surgical resection.


Resectable Merkel Cell Carcinoma

description: Merkel cell carcinoma that is amenable to surgical resection.


Resectable Digestive System Carcinoma

description: Digestive system carcinoma that is amenable to surgical resection.


Resectable Skin Squamous Cell Carcinoma

description: Skin squamous cell carcinoma that is amenable to surgical resection.


name: Localized Resectable Adult Liver Carcinoma

description: A localized hepatocellular carcinoma or intrahepatic cholangiocarcinoma that occurs during adulthood and it is amenable to surgical resection.


name: Resectable Head and Neck Squamous Cell Carcinoma

description: Squamous cell carcinoma of the head and neck which is amendable to surgical removal.


name: Resectable Ampulla of Vater Adenocarcinoma

description: Ampulla of Vater adenocarcinoma that is amenable to surgical resection.


Resectable Appendix Carcinoma

description: Appendix carcinoma that is amenable to surgical resection.


Resectable Gastric Adenocarcinoma

description: Gastric adenocarcinoma that is amenable to surgical resection.


Resectable Endometrial Carcinoma

description: Endometrial carcinoma that is amenable to surgical resection.


Resectable Skin Carcinoma

description: Skin carcinoma that is amenable to surgical resection.


Small intestine carcinoma resectable

description: Carcinoma of the small intestine amendable to resection.


Resectable Colon Carcinoma

description: Colon carcinoma that is amenable to surgical resection.


Resectable Esophageal Carcinoma

description: Esophageal carcinoma that is amenable to surgical resection.


Resectable Gallbladder Adenocarcinoma

description: Gallbladder adenocarcinoma that is amenable to surgical resection.


name: Localized Resectable Adult Hepatocellular Carcinoma

description: A localized hepatocellular carcinoma that occurs during adulthood and it is amenable to surgical resection.


name: Resectable Gastroesophageal Junction Adenocarcinoma

description: Gastroesophageal junction adenocarcinoma that is amenable to surgical resection.


Resectable Cervical Carcinoma

description: Cervical carcinoma that is amenable to surgical resection.


Carcinoma duodenum resectable

description: Carcinoma of the duodenum amendable to surgical removal.


Resectable Colorectal Carcinoma

description: Colorectal carcinoma that is amenable to surgical resection.


Carcinoma liver resectable

description: A hepatocellular carcinoma that is amenable to surgical resection.


Resectable Esophageal Adenocarcinoma

description: Esophageal adenocarcinoma that is amenable to surgical resection.


Resectable Bladder Urothelial Carcinoma

description: Bladder urothelial carcinoma that is amenable to surgical resection.


Penile Cancer pT4 TNM Finding v7

description: Penile cancer with tumor invading other adjacent structures. (from AJCC 7th Ed.)


Penile Cancer Pathologic TNM Finding v7

description: A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v7 classification system.  Complete resection of the primary site with appropriate margins is required for pathologic classification.  (from AJCC 7th Ed.)


Penile Cancer pT1 TNM Finding v7

description: Penile cancer with tumor invading subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4), or tumor invading subepithelial connective tissue with lymph vascular invasion or is poorly differentiated. (from AJCC 7th Ed.)


Penile Cancer pN0 TNM Finding v7

description: Penile cancer with no regional lymph node metastasis. (from AJCC 7th Ed.)


name: Penile Cancer Pathologic Regional Lymph Nodes TNM Finding v7

description: A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.  Pathologic stage definitions are based on biopsy or surgical excision findings.  (from AJCC 7th Ed.)


Penile Cancer pTa TNM Finding v7

description: Penile cancer with a finding of noninvasive verrucous carcinoma.  Note: Broad pushing penetration (invasion) is permitted; destructive invasion is against this diagnosis. (from AJCC 7th Ed.)


Penile Cancer pTis TNM Finding v7

description: Penile cancer with a finding of carcinoma in situ. (from AJCC 7th Ed.)


Penile Cancer pNX TNM Finding v7

description: Penile cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 7th Ed.)


Penile Cancer pTX TNM Finding v7

description: Penile cancer in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)


Penile Cancer pT0 TNM Finding v7

description: Penile cancer with no evidence of a primary tumor. (from AJCC 7th Ed.)


Penile Cancer pT3 TNM Finding v7

description: Penile cancer with tumor invading urethra. (from AJCC 7th Ed.)


name: Penile Cancer Pathologic Distant Metastasis TNM Finding v7

description: A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for penile cancer. (from AJCC 7th Ed.)


name: Penile Cancer Pathologic Primary Tumor TNM Finding v7

description: A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.